137 related articles for article (PubMed ID: 28870898)
1. Inhibitory Activity of Iron Chelators ATA and DFO on MCF-7 Breast Cancer Cells and Phosphatases PTP1B and SHP2.
Kuban-Jankowska A; Sahu KK; Gorska-Ponikowska M; Tuszynski JA; Wozniak M
Anticancer Res; 2017 Sep; 37(9):4799-4806. PubMed ID: 28870898
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2.
Kostrzewa T; Sahu KK; Gorska-Ponikowska M; Tuszynski JA; Kuban-Jankowska A
Drug Des Devel Ther; 2018; 12():4139-4147. PubMed ID: 30584278
[TBL] [Abstract][Full Text] [Related]
3. Lipoic Acid Decreases the Viability of Breast Cancer Cells and Activity of PTP1B and SHP2.
Kuban-Jankowska A; Gorska-Ponikowska M; Wozniak M
Anticancer Res; 2017 Jun; 37(6):2893-2898. PubMed ID: 28551626
[TBL] [Abstract][Full Text] [Related]
4. Benzo[c][1,2,5]thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
Wang WL; Chen XY; Gao Y; Gao LX; Sheng L; Zhu J; Xu L; Ding ZZ; Zhang C; Li JY; Li J; Zhou YB
Bioorg Med Chem Lett; 2017 Dec; 27(23):5154-5157. PubMed ID: 29100798
[TBL] [Abstract][Full Text] [Related]
5. Aurintricarboxylic acid structure modifications lead to reduction of inhibitory properties against virulence factor YopH and higher cytotoxicity.
Kuban-Jankowska A; Sahu KK; Gorska M; Niedzialkowski P; Tuszynski JA; Ossowski T; Wozniak M
World J Microbiol Biotechnol; 2016 Oct; 32(10):163. PubMed ID: 27562597
[TBL] [Abstract][Full Text] [Related]
6. Docosahexaenoic Acid Inhibits PTP1B Phosphatase and the Viability of MCF-7 Breast Cancer Cells.
Kuban-Jankowska A; Gorska-Ponikowska M; Sahu KK; Kostrzewa T; Wozniak M; Tuszynski J
Nutrients; 2019 Oct; 11(11):. PubMed ID: 31652764
[TBL] [Abstract][Full Text] [Related]
7. Ethacrynic acid inhibits STAT3 activity through the modulation of SHP2 and PTP1B tyrosine phosphatases in DU145 prostate carcinoma cells.
Lee YJ; Song H; Yoon YJ; Park SJ; Kim SY; Cho Han D; Kwon BM
Biochem Pharmacol; 2020 May; 175():113920. PubMed ID: 32201212
[TBL] [Abstract][Full Text] [Related]
8. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.
Lang J; Zhao X; Wang X; Zhao Y; Li Y; Zhao R; Cheng K; Li Y; Han X; Zheng X; Qin H; Geranpayehvaghei M; Shi J; Anderson GJ; Hao J; Ren H; Nie G
ACS Nano; 2019 Feb; 13(2):2176-2189. PubMed ID: 30676731
[TBL] [Abstract][Full Text] [Related]
9. PTP1B phosphatase as a novel target of oleuropein activity in MCF-7 breast cancer model.
Przychodzen P; Kuban-Jankowska A; Wyszkowska R; Barone G; Bosco GL; Celso FL; Kamm A; Daca A; Kostrzewa T; Gorska-Ponikowska M
Toxicol In Vitro; 2019 Dec; 61():104624. PubMed ID: 31419504
[TBL] [Abstract][Full Text] [Related]
10. Redox process is crucial for inhibitory properties of aurintricarboxylic acid against activity of YopH: virulence factor of Yersinia pestis.
Kuban-Jankowska A; Sahu KK; Niedzialkowski P; Gorska M; Tuszynski JA; Ossowski T; Wozniak M
Oncotarget; 2015 Jul; 6(21):18364-73. PubMed ID: 26286963
[TBL] [Abstract][Full Text] [Related]
11. In vitro chelating, cytotoxicity, and blood compatibility of degradable poly(ethylene glycol)-based macromolecular iron chelators.
Rossi NA; Mustafa I; Jackson JK; Burt HM; Horte SA; Scott MD; Kizhakkedathu JN
Biomaterials; 2009 Feb; 30(4):638-48. PubMed ID: 18977029
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of heterocyclic bis-aryl amides as novel Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
Satheeshkumar R; Zhu R; Feng B; Huang C; Gao Y; Gao LX; Shen C; Hou TJ; Xu L; Li J; Zhu YL; Zhou YB; Wang WL
Bioorg Med Chem Lett; 2020 Jun; 30(11):127170. PubMed ID: 32273218
[TBL] [Abstract][Full Text] [Related]
13. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma.
Brard L; Granai CO; Swamy N
Gynecol Oncol; 2006 Jan; 100(1):116-27. PubMed ID: 16203029
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
[TBL] [Abstract][Full Text] [Related]
15. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.
Komoto K; Nomoto T; El Muttaqien S; Takemoto H; Matsui M; Miura Y; Nishiyama N
Cancer Sci; 2021 Jan; 112(1):410-421. PubMed ID: 32770631
[TBL] [Abstract][Full Text] [Related]
16. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
17. PTP1B suppresses prolactin activation of Stat5 in breast cancer cells.
Johnson KJ; Peck AR; Liu C; Tran TH; Utama FE; Sjolund AB; Schaber JD; Witkiewicz AK; Rui H
Am J Pathol; 2010 Dec; 177(6):2971-83. PubMed ID: 20952588
[TBL] [Abstract][Full Text] [Related]
18. High-Dose Deferoxamine Treatment Disrupts Intracellular Iron Homeostasis, Reduces Growth, and Induces Apoptosis in Metastatic and Nonmetastatic Breast Cancer Cell Lines.
Bajbouj K; Shafarin J; Hamad M
Technol Cancer Res Treat; 2018 Jan; 17():1533033818764470. PubMed ID: 29562821
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs.
Potuckova E; Jansova H; Machacek M; Vavrova A; Haskova P; Tichotova L; Richardson V; Kalinowski DS; Richardson DR; Simunek T
PLoS One; 2014; 9(2):e88754. PubMed ID: 24586383
[TBL] [Abstract][Full Text] [Related]
20. Desferrioxamine-caffeine shows improved efficacy in chelating iron and depleting cancer stem cells.
Li B; Espósito BP; Wang S; Zhang J; Xu M; Zhang S; Zhang Z; Liu S
J Trace Elem Med Biol; 2019 Mar; 52():232-238. PubMed ID: 30732888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
